Data quality in predictive toxicology: reproducibility of rodent carcinogenicity experiments. by Gottmann, E et al.
Environmental Health Perspectives • VOLUME 109 | NUMBER 5 | May 2001 509
Data Quality in Predictive Toxicology: Reproducibility of Rodent
Carcinogenicity Experiments
Eva Gottmann,1,2 Stefan Kramer,3 Bernhard Pfahringer,4 and Christoph Helma1,2,3
1Institute for Cancer Research, and 2Institute for Environmental Hygiene, University Vienna, Vienna, Austria; 3Institute for Computer Science,
Machine Learning Lab, University Freiburg, Freiburg, Germany; 4Austrian Research Institute for Artiﬁcial Intelligence, Vienna, Austria
The development of structure–activity rela-
tionships (SARs) is gaining more and more
importance in predictive toxicology and risk
assessment. These models rely on the com-
parison of chemical structures and their
properties with their toxicologic effects and
can be used for the prediction of adverse
effects of chemicals, but they are also valu-
able tools to investigate questions of scien-
tiﬁc interest (e.g., toxicologic mechanisms).
Each SAR study needs reliable chemical and
biologic data, but this aspect is neglected in
most investigations. Few systemic studies are
available for the development of SAR mod-
els. This article presents a discussion about
the reliability of toxicologic data in SAR
models and risk assessment. In a previous
paper (1), we covered the identiﬁcation and
representation of chemical structures and the
calculation of chemical properties.
The database we used for our investiga-
tion was the Carcinogenic Potency Database
(CPDB) (2). It contains detailed informa-
tion from long-term in vivo carcinogenicity
experiments for 1,289 structurally diverse
(noncongeneric) compounds. It consists of
two major parts. One data set contains the
results of carcinogenicity experiments per-
formed by the National Cancer Institute
(NCI) and the National Toxicology
Program (NTP); the other part contains car-
cinogenicity assays from the general litera-
ture that meet certain quality criteria (e.g.,
concerning administration of compounds,
duration of experiments, number of test and
control animals, availability of original data).
One hundred twenty-one chemicals were
tested in both parts [Table 1; the complete
data set is available from the authors (3)].
This overlap allows the comparison of repli-
cate carcinogenicity experiments with the
same compound.
Our intention was to investigate the relia-
bility of rodent carcinogenicity assays for SAR
studies and risk assessment. This is usually
ascertained by repeating experiments with the
same substance under the same test condi-
tions. Rodent carcinogenicity experiments,
however, are too time consuming and expen-
sive to replicate experiments for a sufﬁciently
large number of compounds. Therefore, we
compared carcinogenicity experiments of the
overlapping compounds from the NCI/NTP
and the literature parts, although they were
not performed with identical protocols. This
closely resembles the real-world situation for
the development of SAR models, where results
from different sources and different protocols
are combined to obtain a larger database. 
One measure of reproducibility is con-
cordance, the number or percentage of chem-
icals that are classified the same way in
different data sets. More precisely, we pre-
pared ﬁrst an overall rodent carcinogenicity
classification because classifications neglect-
ing additional information such as species,
sex, and strain are often used as the basis for
SAR studies and risk assessment. In further
comparisons we considered species- and sex-
speciﬁc effects because it was recommended
to use these parameters in SAR models (4)
and for the registration of chemicals. We also
intended to ﬁnd out whether it is sensible to
develop organ-specific SARs and to what
extent additional biologic information inﬂu-
ences the accuracy of SAR models and risk
assessment. We investigated whether addi-
tional toxicologic information, in our case
mutagenicity, can help identify carcinogens
and whether it should be included in SAR
studies. Finally, we compared the quantita-
tive measure for carcinogenic potency, the
tumorigenic dose rate 50 (TD50) (5,6) to
find out if it is sensible to predict TD50
values and to distinguish between strong and
weak carcinogens.
Methods 
Source of data. Toxicologic data were
obtained from the CPDB compiled by Gold
et al. (2). This is the most extensive and
detailed publicly available carcinogenicity
database, with results of chronic, long-term
animal cancer tests. Both qualitative and
quantitative information on positive and
negative experiments are given, including all
bioassays from the NCI/NTP and results
from the general literature that meet a set of
inclusion criteria (2). The CPDB contains
experiments with 1,298 chemicals. For each
experiment, the following information is
included: species, strain, and sex of test ani-
mals; features of the experimental protocol
such as route of administration, duration of
dosing, dose levels in milligrams per kilo-
gram of body weight per day, duration of
the experiment; histopathology and tumor
incidence; carcinogenic potency (TD50) and
its statistical significance; shape of the
dose–response curve; authors’ opinion as to
carcinogenicity; and literature citation (2).
The CPDB data were converted to Prolog
facts for Machine Learning Experiments and
data analysis within Sicstus Prolog (7).
Statistical evaluation. Generally the
results of our investigations take the form
shown in Table 2, which summarizes concor-
dant and discordant classiﬁcations (carcino-
gen/noncarcinogen) from two different data
sources (NCI/NTP, literature). To analyze
the degree to which classiﬁcations of items are
associated, we used the G index according to
Holley and Guilford (8) and the association
coefﬁcient according to Cole (9). Given such
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Articles
We compared 121 replicate rodent carcinogenicity assays from the two parts (National Cancer
Institute/National Toxicology Program and literature) of the Carcinogenic Potency Database
(CPDB) to estimate the reliability of these experiments. We estimated a concordance of 57%
between the overall rodent carcinogenicity classiﬁcations from both sources. This value did not
improve substantially when additional biologic information (species, sex, strain, target organs)
was considered. These results indicate that rodent carcinogenicity assays are much less repro-
ducible than previously expected, an effect that should be considered in the development of struc-
ture–activity relationship models and the risk assessment process. Key words: carcinogenicity,
machine learning, predictive toxicology, quality assurance, structure–activity relationships.
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http://ehpnet1.niehs.nih.gov/docs/2001/109p509-514gottmann/abstract.htmla table consisting of four entries, a, b, c, and
d, as defined in Table 2 (inadequate results
were not considered in statistical analysis),
these statistics are deﬁned as follows. 
The G index is deﬁned as 
It is a measure of the relative increase or
decrease in the number of concordant classi-
fications. The assumption of independence
(H0: G = 0) is tested using the sign test, either
exactly or using the normal distribution: 
Given positive association, the association
coefﬁcient according to Cole (9) is deﬁned as
follows: 
The asymptotic test for C = 0 is 
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Table 1. Identiﬁcation of the 121 compounds tested in the NTP and literature part of the CPDB. 
Results from carcinogenicity assays are available from the authors (3). 
Abbreviation Chemical CAS No.
1te 1,1,1-Trichloroethane, technical grade 71-55-6
2dc 1,2-Dichloroethane 107-06-2
3db 3,3’-Dimethoxybenzidine · 2HCl 20325-40-0
ald Aldrin 309-00-2
ant 2-Amino-5-nitrothiazole 121-66-4
apc Aspirin, phenacetin, and caffeine 8003-03-0
azb Azobenzene 103-33-3
azc 5-Azacytidine 320-67-2
b38 C.I. Direct black 38 1937-37-7
bcm Bromodichloromethane 75-27-4
bde 1,3-Butadiene 106-99-0
ben Benzene 71-43-2
bht Butylated hydroxytoluene 128-37-0
bna Benzyl acetate 140-11-4
bzo Coumarin 91-64-5
cap Captan 133-06-2
ccc (2-Chloroethyl)trimethylammonium chloride 999-81-5
cci Cyanamide, calcium 156-62-7
cdu 3-(p-Chlorophenyl)-1,1-dimethylurea 150-68-5
chb Chlorobenzilate 510-15-6
chd Chlordane, technical grade 57-74-9
chf Chloroform 67-66-3
cms C.I. Food Red 3 3567-69-9
cpm Chlorpheniramine maleate 113-92-8
ctl 4-Chloro-o-toluidine · HCl 3165-93-3
dan 2,4-Diaminoanisole sulfate 39156-41-7
day C.I. Pigment yellow 12 6358-85-6
dbe 1,2-Dibromoethane 106-93-4
dcv Dichlorvos 62-73-7
ddt DDT 50-29-3
deu N,N’-Diethylthiourea 105-55-5
dhm Diphenhydramine · HCl 147-24-0
dhx Di(2-ethylhexyl)phthalate 117-81-7
die Dieldrin 60-57-1
dio 1,4-Dioxane 123-91-1
dis Tetraethylthiuram disulﬁde 97-77-8
dmz 3,3’-Dimethylbenzidine · 2HCl 612-82-8
dph 5,5-Diphenylhydantoin 57-41-0
dr9 D & C Red No. 9 5160-02-1
dsa Daminozide 1596-84-5
edd p,p’-Ethyl-DDD 72-56-0
egl Eugenol 97-53-0
ela Ethyl acrylate 140-88-5
end Endrin 72-20-8
eod Ethylene oxide 75-21-8
eta Ethionamide 536-33-4
ete Ethyl tellurac 20941-65-5
eth Ethylene thiourea 96-45-7
fﬂ Furfural 98-01-1
ﬂ2 Trichloroﬂuoromethane 75-69-4
fsz 5-Nitro-2-furaldehyde semicarbazone 59-87-0
fy6 FD & C Yellow No. 6 2783-94-0
gar Tetrachlorvinphos 961-11-5
gly Glycidol 556-52-5
hb1 HC Blue No. 1 2784-94-3
hcp Hexachlorophene 70-30-4
hct Hydrochlorothiazide 58-93-5
hep Heptachlor 76-44-8
hql 8-Hydroxyquinoline 148-24-3
hya Acetaminophen 103-90-2
hyq Hydroquinone 123-31-9
Abbreviation Chemical CAS No.
kep Kepone 143-50-0
las Lasiocarpine 303-34-4
ldt Lead dimethyldithiocarbamate 19010-66-3
lin γ -1,2,3,4,5,6-Hexachlorocyclohexane 58-89-9
mbr Methyl bromide 74-83-9
mbt 2-Mercaptobenzothiazole 149-30-4
mca Monochloroacetic acid 79-11-8
mcl Mercuric chloride 7487-94-7
mop 8-Methoxypsoralen 298-81-7
mrx Mirex 2385-85-5
mxc Methoxychlor 72-43-5
myc Methylene chloride 75-09-2
nac 5-Nitroacenaphthene 602-87-9
nat Nitrilotriacetic acid, trisodium salt, monohydrate 18662-53-8
nff 1-[(5-Nitrofurfurylidene)amino]hydantoin 67-20-9
nha 3-Nitro-4-hydroxyphenylarsonic acid 121-19-7
nta Nitrilotriacetic acid 139-13-9
oca Ochratoxin A 303-47-9
pb1 Aroclor 1254 11097-69-1
pbt Phenylbutazone 50-33-9
pch 2,3,4,5,6-Pentachlorophenol (Dowicide EC-7) 87-86-5
pcm Picloram, Technical grade 1918-02-1
pct 2,3,4,5,6-Pentachlorophenol, technical grade 87-86-5
pdd p,p’-DDD 72-54-8
pde p,p’-DDE 72-55-9
phn 1-Phenylazo-2-naphthol 842-07-9
pip Piperonyl butoxide 51-03-6
pna Phenyl-β -naphthylamine 135-88-6
pnb Pentachloronitrobenzene 82-68-8
pni p-Nitroaniline 100-01-6
prb Procarbazine · HCl 366-70-1
prg Propyl gallate 121-79-9
prl Propylene 115-07-1
prp 1,2-Propylene oxide 75-56-9
psu Piperonyl sulfoxide 120-62-7
qrc Quercetin 117-39-5
red N-Nitrosodiphenylamine 86-30-6
ros p-Rosaniline · HCl 569-61-9
rsp Reserpine 50-55-5
saz Azide, sodium 26628-22-8
sdc Sodium diethyldithiocarbamate trihydrate 148-18-5
sma Malonaldehyde, sodium salt 24382-04-5
sof Fluoride, sodium 7681-49-4
sta Tin (II) chloride 7772-99-8
sty Styrene 100-42-5
tcb 2,4,6-Trichlorophenol 88-06-2
tcd 2,3,7,8-Tetrachlorodibenzo-p-dioxin 1746-01-6
tce Trichloroethylene 79-01-6
tda 4,4’-Thiodianiline 139-65-1
tep THIO-TEPA 52-24-4
thd Endosulfan 115-29-7
tol Toluene 108-88-3
tou o-Toluidine · HCl 636-21-5
trf Triﬂuralin, technical grade 1582-09-8
trs Tris(2,3-dibromopropyl)phosphate 126-72-7
try L-Tryptophan 73-22-3
tub Rotenone 83-79-4
vdc Vinylidene chloride 75-35-4
zdd Zinc dimethyldithiocarbamate 137-30-4
zec Mexacarbate 315-18-4
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indicates an ideal association. In Table 3, we
summarize the results for these statistical
tests, include an interpretation (using the
standard interpretation scale for the normal
distribution), and rank the results accord-
ingly (Table 2). 
Results 
As described above, the CPDB consists of
two different subsets, the results from the
NCI/NTP and the results from the general
literature. From experiments on 1,298
chemical agents, only 121 chemicals were
tested in both the NCI/NTP and the litera-
ture parts. We used this overlapping part of
the CPDB for the present analysis. 
Overall rodent carcinogenicity classiﬁca-
tion. Our aim was to quantify the concor-
dance/discordance between carcinogenicity
classifications from both data sets. Classi-
fications were based on authors’ opinions
because authors consider more than statisti-
cal signiﬁcance alone [historical control rates
for particular sites, survival and latency,
and/or dose response (2)]. A compound was
classified as a carcinogen if a positive result
was obtained in at least one experiment. 
The results are summarized in Table 4,
which shows that an unexpectedly low pro-
portion of these 121 compounds were classi-
ﬁed concordantly in both parts as carcinogens
or noncarcinogens. Only 69 (57%) chemicals
had concordant authors’ opinions, 57%
(39/69) of the chemicals were consistently
classified as positive, and 43% (30/69) had
negative results in both sources (Table 4). 
Species- and sex-speciﬁc effects. We stud-
ied the detail, considering the reproducibility
of species and sex speciﬁc effects. Evans et al.
(10) already noted that species- and sex-spe-
ciﬁc tumorigenicity is one of the parameters
that should be considered when evaluating
results from animal cancer studies. Our cal-
culations gave the following results (Table
5): from 70 investigations with mice, 49%
had concordant results; from 71 experiments
with rats, 62% were concordant. The con-
sideration of sexes gave similar results. The
concordance of male mice was 46%, of
female mice 36%, of male rats 55%, and of
female rats 69% (Table 5). 
z
c
ac cd
Na bb d
=
+ () + ()
+ () + ()
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Table 2. Deﬁnition of variables for the statistical tests.
Carcinogena Noncarcinogenb Literature
Carcinogena ab a + b
Noncarcinogenb cd c + d
NCI/NTP a + cb + dN = a + b + c + d
aAt least one experiment is evaluated as positive. bAt least one experiment is evaluated as negative and no experiment is
evaluated as positive. 
Table 4. A comparison of the classiﬁcation in the NCI/NTP and literature parts of the CPDB.
Carcinogena Noncarcinogenb Inadequatec Literature
Carcinogena 39 13 1 53
Noncarcinogenb 20 30 0 50
Inadequatec 10 8 0 18
NCI/NTP 69 51 1 121
Concordant classiﬁcation: 69 compounds (57%); discordant classiﬁcation: 52 compounds (43%).
aAt least one experiment is evaluated as positive. bAt least one experiment is evaluated as negative and no experiment is
evaluated as positive. cExperiments are evaluated neither positive nor negative. 
Table 3. Overview of the statistical evaluation.
G index z Inta Cole z Int Rank
Overall 0.353 –3.565 Very high 0.407 3.578 Very high 3
Mice 0.283 –2.060 High 0.351 3.095 Very high 6
Rats 0.375 –3.000 Very high 0.398 2.991 Very high 3
Female mice 0.200 –1.264 Low 0.205 1.433 Low 7
Male mice 0.333 –2.160 High 0.467 4.058 Very high 5
Female rats 0.522 –3.539 Very high 0.489 3.481 Very high 1
Male rats 0.373 –2.661 Very high 0.440 2.678 Very high 2
Single sp./multiple sp.b 0.152 –0.870 Low 0.313 3.022 Very high 8
Single cat./multiple cat.c 0.030 –0.174 Low — — — 9
aInterpretation according to the standard scale for the normal distribution.bSingle-species/multiple-species carcinogens.
cSingle-category/multiple-categories carcinogens. 
Table 5. A comparison of the classiﬁcation with consideration on species and sex in the NCI/NTP and literature parts of the CPDB.
Mice Rats
Carcinogenica Noncarcinogenicb Inadequatec Literature Carcinogenica Noncarcinogenicb Inadequatec Literature
Males
Carcinogenica 11 10 1 22 15 6 1 22
Noncarcinogenicb 4 17 1 22 10 20 3 33
Inadequatec 41 2 1 1 745 0 9
NCI/NTP 19 39 3 61 29 31 4 64
Concordant  28 compounds (46%) 35 compounds (55%)
Discordant  33 compounds (54%) 29 compounds (45%)
Females
Carcinogenica 99 1 1 9 1 0 6 1 1 7
Noncarcinogenicb 7 15 3 25 5 25 1 31
Inadequatec 61 3 3 2 21 1 1 3
NCI/NTP 22 37 7 66 16 32 3 51
Concordant  24 compounds (36%) 35 compounds (69%)
Discordant  42 compounds (64%) 16 compounds (31%)
Both
Carcinogenica 15 12 0 27 20 9 1 30
Noncarcinogenicb 7 19 0 26 11 24 0 35
Inadequatec 41 2 1 1 742 0 6
NCI/NTP 26 43 1 70 35 35 1 71
Concordant  34 compounds (49%) 44 compounds (62%)
Discordant  36 compounds (51%)  27 compounds (38%)
aAt least one experiment is evaluated as positive. bAt least one experiment is evaluated as negative, and no experiment is evaluated as positive. cExperiments are evaluated as neither
positive nor negative. There is obviously a difference between
the reproducibility of experiments with mice
and rats, although mice and rats are closely
related. The tests on rats seem to be far more
reproducible. Concerning the sexes, we could
not observe clear trends. On one hand, the
reproducibility of experiments on male mice
was better than on female mice; on the other
hand, experiments on female rats had a better
concordance than those on male rats. It is
notable that experiments with female mice
are, with a high probability, statistically inde-
pendent (Table 3). 
Carcinogens in mice are probably heavily
influenced by the strain (3), which shows
that the selection of the strains is another
important source of variability in the data.
In the NCI/NTP studies, 3 different rat
strains and 1 mouse strain were used for
experiments with the 121 overlapping chem-
icals; in the literature, 29 different rat strains
and 37 different mice strains were tested.
The most frequently used strains in both
parts of the CPDB were Fischer F344/N rats
and B6C3F1 mice. The concordance for
these strains was 53% (9/17) for male rats,
64% (7/11) for female rats, 39% (15/38) for
male mice, and 33% (13/40) for female
mice. These values are close to the overall
concordance (Table 5) and indicate that the
poor reproducibility of carcinogenicity assays
may not be due to different strains in the
NCI/NTP and literature parts of the CPDB.
Another factor that influences the out-
come of carcinogenicity assays is the route of
administration. Unfortunately, splitting the
CPDB in respect to administration routes
resulted in data sets too small for a detailed
analysis. Thus, we currently do not know
whether or not the route of administration
plays a role in the concordance of results. 
Compounds that are carcinogenic in rats
and mice are considered more harmful than
those affecting only one species. Therefore,
we grouped the compounds into one-species
carcinogens or two-species carcinogens and
compared the classiﬁcations of the two data
sets. For carcinogenic compounds, 48%
(16/33) were one-species carcinogens and
52% (17/33) were two-species carcinogens
in the NCI/NTP studies; in the literature,
73% (24/33) were one-species carcinogens
and 27% (9/33) were two-species carcino-
gens. A comparison of NCI/NTP data with
data from the literature showed that 58%
(19/33) of the compounds were classified
concordantly (Table 6), but with low coefﬁ-
cients of association (Table 3) and without
an indication for a better concordance as
obtained for the overall data set. From con-
cordant one-species carcinogens, only 31%
(4/13) affected the same species. 
Target-organ speciﬁcity. To facilitate tar-
get organ comparisons between rats and mice,
we grouped the tissue codes for the target sites
into 11 basic target categories: 1, digestive sys-
tem; 2, liver; 3, cardiovascular system; 4,
endocrine system; 5, hematopoietic system; 6,
integumentary system; 7, nervous system,
brain, and sensory organs; 8, reproductive sys-
tem; 9, respiratory system; 10, urinary tract;
and 11, other (body regions, muscle, skeleton,
etc.) excluding some unspeciﬁc tissue codes
[all tumors, more than one tumor type;
tumor types specified in published paper
(mix), more than one tumor type; combined
by NCI/NTP (MXA), more than one tumor
type; combined by Berkeley (MXB) and
tumor, or more than one tumor type; and
tumor types not speciﬁed in paper (2)]. For
33 common carcinogens in NCI/NTP and in
literature, the liver is the most frequent target
site, which is in agreement with other investi-
gations (2) (Figure 1). 
Subsequently, we classified the com-
pounds either as one-category carcinogens or
as multicategory carcinogens, because multi-
site and multispecies animal carcinogens are
considered to pose a greater threat to humans
than single-site/species carcinogens (11). Our
analysis showed that in the NCI/NTP part,
the minority (36%; 12/33) of the chemicals
was classiﬁed as one-category carcinogens and
the majority (64%; 21/33) was multicategory
carcinogens. In the literature we found similar
results: 42% (14/33) of compounds were clas-
siﬁed as one-category carcinogens and 56%
(19/33) were multicategory carcinogens. 
A comparison of NCI/NTP data with
data from the literature showed that 52% of
the chemicals occurring in both data sets were
concordantly classiﬁed. The majority of the
compounds were multicategory carcinogens
(Table 7), but less than 50% of these com-
pounds caused tumors in the same categories.
(The statistical analysis summarized in Table
3 reveals a low probability that NCI/NTP
and literature results are associated). 
Comparison of species carcinogens and
organ-category carcinogens. Our results indi-
cate a connection between the number of
affected species and the number of positive
categories. It seems that chemicals classiﬁed
as one-species carcinogens correlate with
one-category carcinogens and that there is
also a correlation between two-species car-
cinogens and multicategory carcinogens. 
In both parts of the CPDB, the majority
of compounds classified as one-species car-
cinogens were also one-category carcinogens
(NCI/NTP, 9/16; literature, 13/24), and the
majority of chemicals classiﬁed as two-species
carcinogens were also multicategory carcino-
gens (NCI/NTP, 14/18; literature, 8/9;
Table 8), but only 33% of the compounds
were grouped concordantly in both parts. 
Quantitative effects. For the evaluation of
carcinogenic potency, we used the most
potent TD50 for each compound. The TD50
is deﬁned as the dose rate in milligrams per
kilogram of body weight per day, which if
administered chronically for the standard life
Articles • Gottmann et al.
512 VOLUME 109 | NUMBER 5 | May 2001 • Environmental Health Perspectives
Figure 1. Frequency of target organs in the NTP/NCI and the literature part of the CPDB.
Table 6. A comparison of one-species and two-species carcinogens in the NCI/NTP and literature parts
of the CPDB
One speciesa Two speciesb Literature
One speciesa 13 11 24
Two speciesb 369
NCI/NTP 16 17 33
Concordant classiﬁcation: 19 compounds (57%); discordant classiﬁcation: 14 compounds (43%).
aCompounds are carcinogenic in one species (mouse or rat). bCompounds are carcinogenic in both species (mouse and rat). 
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LITspan of the species will halve the probability
of remaining tumorless throughout that
period (5). A low TD50 value indicates a
potent carcinogen, whereas a high value indi-
cates a weak one. If there is only one positive
test on the chemical in the species, then the
most potent TD50 value from that test is
reported in the CPDB. When more than one
experiment is positive, in order to use all the
available data, the reported potency value is
the harmonic mean of the most potent TD50
values from each positive experiment (2).
A comparison of the compounds present
in both (NCI/NTP and literature) parts of
the CPDB showed that the correlation of
quantitative data is similar to qualitative clas-
siﬁcations, rather low (r2 = 0.63; Figure 2).
This comparison may underestimate the
reproducibility of carcinogenicity experi-
ments because, as mentioned several times,
only NTP/NCI experiments were conducted
with a standardized protocol. 
Among chemicals positive in both species
(NCI/NTP, 16, literature, 6), the experi-
ments on rats are not only more reproducible
but also much more sensitive than tests on
mice. These results are in accordance with
calculations on the whole CPDB, carried out
by Gold and Zeiger (2). Furthermore, in the
NCI/NTP part, the most potent TD50 values
were much lower for rats, in contrast to the
results in the literature part, where the TD50
values for mice were more potent (Table 9). 
Mutagenicity effects. Mutations are one
of the most important mechanisms in chemi-
cal carcinogenesis (4,11). The Salmonella
mammalian microsome mutagenicity (Ames)
test was designed to measure mutations using
several strains of the Salmonella typhimurium
(12). It is well known from the literature that
the Salmonella assay identiﬁes a high propor-
tion of carcinogenic chemicals, but a number
of carcinogens lack mutagenic potential in
this assay. Trying to identify the nongeno-
toxic chemicals with carcinogenic potential
represents a major unsolved problem, which
shows that rodent carcinogenicity tests can-
not, at present, be replaced by the Salmonella
assay or other short-term tests. 
For our comparisons we used the Ames
test evaluation from Gold and Zeiger (2).
The number of compounds occurring in
NCI/NTP and literature with additional
mutagenicity data was too small for calcula-
tions; therefore, we used data from the larger
non-overlapping sets. Mutagenicity data
were available for 178 chemicals from the
NCI/NTP part and for 272 compounds
from the literature part. In both subsets the
majority of carcinogenic compounds was
also mutagenic; 57% (102/178) of the
chemicals in the NCI/NTP experiments and
64% (173/272) in the literature investiga-
tions were Ames positive. The majority of
noncarcinogenic compounds gave negative
results in the Salmonella assay (119/169
NCI/NTP, 94/149 literature; Table 10). 
For further analysis we used only the
NCI/NTP data set because only these experi-
ments were conducted under standardized
conditions. We tried to determine if muta-
genicity data can be used to identify multi-
species carcinogens and multicategory
carcinogens. The data from the NCI/NTP
showed that the majority of one-category car-
cinogens (52%; 44/85) as well as one-species
carcinogens (55%; 54/98) were Ames nega-
tive, whereas the majority of multicategory
carcinogens (66%; 61/93) and two-species
carcinogens (73%; 58/80) were Ames positive
(Table 11). 
This analysis conﬁrms that genotoxic car-
cinogens are generally characterized by an
ability to cause tumors in multiple species and
at multiple sites (13,14) whereas nongeno-
toxic agents tend to exhibit tissue- and
species-specific carcinogenicity (Table 11)
(4,13,15). Results of the Salmonella test are
therefore important for identifying human car-
cinogens and to the development of SAR mod-
els. The high probability of inducing
carcinogenic effects in multiple species is also
demonstrated by the majority of chemicals that
have been shown to cause human cancers (11).
Discussion 
The main observation of our investigation
was an unexpected large discordance between
experimental results from the NCI/NTP and
the literature parts of the CPDB. This leads
to two conclusions. First, differences in
experimental protocols of the NCI/NTP and
literature parts have led to discordant results.
NCI/NTP experiments were performed
under standardized conditions, but in the lit-
erature, experimental protocols vary consid-
erably [although they must meet quality
criteria for inclusion in the CPDB (2)]. Some
chemicals have been tested in the literature
part only with one sex of one species, while
others have multiple tests that include both
sexes and several strains of rats and mice.
Additionally, the number of doses, the range
of doses, the administration route, and the
group size may vary. Thus, different experi-
mental protocols and missing and additional
experiments may be the reason for the low
concordance between both parts of the
CPDB. We were able to demonstrate, how-
ever, that the inclusion of more (species, sex,
strain, organ) specific information did not
improve the reproducibility of the results. 
This may be taken as an indication that
rodent carcinogenicity assays are, in general,
poorly reproducible. This is in clear contra-
diction to earlier results obtained by Gold et
al. (16), where an overall reproducibility of
93% (rats) and 76% (mice) was estimated.
That investigation was based on replicate
experiments of 38 compounds with ham-
sters, rats, and mice published in the general
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Figure 2. Correlation of carcinogenicity TD50 values
from the NTP/NCI and the literature (LIT) part of the
CPDB (r2 = 0.63).
Table 7. A comparison of one-category and multicategory carcinogens in the NCI/NTP and literature
parts of the CPDB.
One categorya Two categoriesb Literature
One categorya 59 1 4
Two categoriesb 71 2 1 9
NCI/NTP 12 21 33
Concordant classiﬁcation: 17 compounds (52%); discordant classiﬁcation: 16 compounds (48%).
aCompounds are carcinogenic in one tissue category. bCompounds are carcinogenic in more than one tissue category.
Table 8. A comparison of one- and two-species carcinogens and one- and multicategory carcinogens in
the NCI/NTP and literature parts of the CPDB.
One/onea One/multib Two/onec Two/multid Literature
One/onea 242 5 1 3
One/multib 431 3 1 1
Two/onec 100 0 1
Two/multid 200 6 8
NCI/NTP 9 7 3 14 33
Concordant classiﬁcation: 11 compounds (33%); discordant classiﬁcation: 22 compounds (67%).
aCompounds are one-species carcinogens and one-category carcinogens. bCompounds are one-species carcinogens
and multicategory carcinogens. cCompounds are two-species carcinogens and one-category carcinogens. dCompounds
are two-species carcinogens and multicategory carcinogens. 
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literature. Looking for an explanation for the
discordance with our results, we realized that
from 47 concordant experiments (sex,
administration route, and target organs were
considered; therefore, the number of experi-
ments is larger than the number of com-
pounds) with rats and mice listed by Gold et
al. (16), 34 results were published by the
same authors. This may have led to a bias
towards identical results, but it may be also
an indicator of the importance of strict
experimental protocols for reproducibility.
In addition, the results may differ for statisti-
cal reasons caused by the different data sets
(size and selection of compounds). 
Based on our data, it is currently impos-
sible to decide between these two explana-
tions, but it seems that the reliability of
rodent carcinogenicity assays was overesti-
mated in previous investigations. To clarify
this point, it will be necessary to compare a
sufficient number of results from standard-
ized assays, which are not publicly available
at this time. Until then, results from rodent
carcinogenicity assays should be treated as
unreliable, which has consequences for SAR
modelers and the risk assessment process. 
SAR models for carcinogenicity are based
on rather poor biologic data. The accuracy of
these SARs is therefore much lower than for
other end points. It is interesting to note that
experiments with rats are more reproducible
than those with mice. It is therefore prudent
to develop species-speciﬁc SAR models. The
inclusion of more speciﬁc (e.g., target organs)
information may make sense from a biologic
viewpoint, but this data set is very unreliable
and may reduce the overall performance of
the SAR model. We assume that data from
standardized tests are more reliable than that
from nonstandardized sources. When adding
data from nonstandardized sources to stan-
dardized ones (e.g., NCI/NTP), it should be
therefore carefully considered whether the
increased amount of data outweighs the addi-
tional variability introduced by data from dif-
ferent sources. As mutagenicity is a good
indicator, especially for multispecies and
multisite carcinogens, this information
should be used in SAR studies. An important
direction for further research is to ﬁnd meth-
ods to incorporate uncertainty indicators in
SAR models and to adequately report the
limitations of the derived models. 
In risk assessment, the consequences of
poor data quality are even more pronounced.
We were able to demonstrate that it is not
only hard to identify carcinogens in general,
but also to identify powerful multispecies and
multiorgan carcinogens reliably. Especially in
this area, highly relevant to public health and
economy, improved quality assurance meth-
ods for biologic assays are urgently needed.
Furthermore, the uncertainty of biologic
information should be adequately considered
in the risk assessment process. 
Summarizing our experience with data
quality in predictive toxicology, we conclude
that biologic data are much less reliable than
chemical data (1). It is impossible to evalu-
ate the quality of standardized rodent car-
cinogenicity experiments, but results from
the general literature have only a poor con-
cordance with results from the NTP. An
independent assessment of standardized car-
cinogenicity assays (e.g., in a round-robin
test) is urgently needed to estimate the real
reproducibility of these tests. We hope that
this paper raises awareness about data quality
issues and its implications in predictive toxi-
cology and risk assessment. 
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Table 11. The distribution of mutagens and nonmutagens on carcinogens and noncarcinogens in the
NCI/NTP and literature parts of the CPDB.
Mutagenicity No. of compounds Percentage
One-species carcinogensa Yes 44/98 45
No 54/98 55
One-category carcinogensb Yes 41/85 48
No 44/85 52
Two-species carcinogensc Yes 58/80 73
No 22/80 27
Multicategory carcinogensd Yes 61/93 66
No 32/93 34
aCompounds are carcinogenic in one species (mouse or rat). bCompounds are carcinogenic in one tissue category.
cCompounds are carcinogenic in both species (mouse and rat). dCompounds are carcinogenic in more than one tissue
category.
Table 9. A comparison of the most potent TD50 values (medians) for those chemicals classified as car-
cinogens in the NCI/NTP and literature parts of the CPDB.
Rats Mice
Data set All  Males Females  All  Males Females
NCI/NTP 6.478 2.365 7.420 32.950 54.100 29.400
Literature 50.750 161.400 70.630 20.680 28.600 15.070
Table 10. The distribution of mutagens and nonmutagens on carcinogens and noncarcinogens in the
NCI/NTP and literature parts of the CPDB.
Data set Classiﬁcation Mutagens Nonmutagens
NCI/NTP Carcinogens 57% (102/178) 43% (76/178)
NCI/NTP Noncarcinogens 30% (50/169) 70% (119/169)
Literature Carcinogens 64% (173/272) 36% (99/272)
Literature Noncarcinogens 37% (55/149) 63% (94/149)